Boehringer Ingelheim snaps up T3 Pharmaceuticals for $508m
Boehringer Ingelheim said its immune-modulatory cancer medicines will benefit from T3 Pharma's advanced technology, supporting the company's oncology…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Nov 23
Boehringer Ingelheim said its immune-modulatory cancer medicines will benefit from T3 Pharma's advanced technology, supporting the company's oncology…
22 Nov 23
Under the agreement, Merck will acquire all the outstanding shares of Massachusetts-based Caraway with earnout milestones related to…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Nov 23
Zevra aims to advance in the development and commercialisation of treatments for rare diseases and support patient communities…
16 Nov 23
Astellas will obtain Propella’s lead candidate PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor intended for the treatment…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Nov 23
The primary focus of the combined entity's lead programmes will be on addressing presbyopia, the age-related decline in…
14 Nov 23
The proposed deal is expected to strengthen and distinguish Telix's position in providing patients with a range of…
09 Nov 23
The deal is expected to strengthen Alfasigma's pipeline, including the addition of a novel fixed-dose combination that has…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Nov 23
CFC's scaled provider group, with over 350 primary care physicians and 500 specialists on platform, manages the medical…
08 Nov 23
Following completion of the Transaction SecureDose became a wholly-owned subsidiary of PharmaDrug
07 Nov 23
ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader intended to treat acute myeloid leukaemia (AML) and other CD33-expressing malignancies,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates